AZ considers options as US gout drug deal backfires
Ironwood tears up licensing agreement after sales disappoint
X
AZ considers options as US gout drug deal backfires
https://pharmaphorum.com/news/az-considers-options-drug-deal-backfires/
Grunenthal
AZ sells migraine drug rights to Grunenthal for $300m
AZ says migraine outside its strategic focus.
Five UK pharma companies “named and shamed” by watchdog
Companies’ actions discredited the industry, says PMCPA.
EU regulator begins publishing detailed study data
European Medicines Agency proactively publishes clinical study reports for first time.
AZ sells US, EU and Latin America rights to gout drug
AZ focused on sales target set by CEO Pascal Soriot.
